Showing 1781-1790 of 2038 results for "".
- Study: Digital Home Monitoring Shows Unique Predictive Value in Disease Progression for AMD Patientshttps://modernod.com/news/study-digital-home-monitoring-shows-unique-predictive-value-in-disease-progression-for-amd-patients/2481190/Notal Vision reported the publication of the second report of the "Analysis of Long-term visual Outcomes of ForeseeHome Remote Telemonitoring (ALOFT)" study results in Ophthalmology Retina. The 10-year retrospective study details the importance of digital remote monitor
- Eyenovia Announces Positive Results From VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopiahttps://modernod.com/news/eyenovia-announces-positive-results-from-vision-2-phase-3-study-of-microline-as-a-potential-on-demand-treatment-for-presbyopia/2481181/Eyenovia announced positive results from its VISION-2 Phase 3 study of MicroLine as a potential topical, on-demand treatment for presbyopia. The VISION-2 study evaluated the safety and efficacy of Eyenovia’s 2% pilocarpine micro-array print (MAP) formulation versus placebo, all administered
- Survey Identifies Diabetic Retinopathy Screening and Care as Top Outreach Eye Care Need in Utahhttps://modernod.com/news/survey-identifies-diabetic-retinopathy-screening-and-care-as-top-outreach-eye-care-need-in-utah/2481172/A recent survey of eye care providers and stakeholders identified screening and care for diabetes-related vision loss as the most urgent need for residents on the Navajo Nation, people experiencing homelessness, former refugees, and underinsured or uninsured Utahns, according to a team of health
- Shore Capital Partners Announces Sale of EyeSouth Partnershttps://modernod.com/news/shore-capital-partners-announces-sale-of-eyesouth-partners/2481146/Shore Capital Partners, a Chicago-based private equity firm, has announced the sale of EyeSouth Partners, an eye care management services organization, to Olympus Partners. Terms of the deal were not disclosed. Shore formed EyeSouth in 2017 with the goal of creating
- Atsena Therapeutics Announces Positive Results from Phase 1/2 Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)https://modernod.com/news/atsena-therapeutics-announces-positive-results-from-phase-iii-clinical-trial-of-atsn-101-for-the-treatment-of-gucy2d-associated-leber-congenital-amaurosis-lca1/2481145/Atsena Therapeutics announced positive results from the phase 1/2 clinical trial of ATSN-101, its lead investigational gene therapy product formerly known as SAR439483, for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). The data demonstrated that su
- Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with XLRPhttps://modernod.com/news/late-breaking-phase-12-data-demonstrates-safety-profile-of-investigational-gene-therapy-botaretigene-sparoparvovec-aav-rpgr-and-sustained-vision-improvement-in-patients-with-xlrp/2481143/MeiraGTx announced the primary results from the phase 1/2 study evaluating the investigational gene therapy botaretigene sparoparvovec (formerly AAV-RPGR) in patients with the inherited retinal disease X-linked retinitis pigmentosa (XLRP) associated with the retinitis pigmentosa GTPase regul
- Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIIIhttps://modernod.com/news/oyster-point-pharma-to-present-new-scientific-analyses-at-world-cornea-congress-viii/2481117/Oyster Point Pharma announced it will present new scientific analyses at World Cornea Congress VIII, which is taking place in Chicago from September 28-29, 2022. “We look forward to presenting our post-hoc analyses on the clini
- MeiraGTx’s Unveils Gene Therapy Manufacturing Facility in Shannon, Irelandhttps://modernod.com/news/meiragtxs-unveils-gene-therapy-manufacturing-facility-in-shannon-ireland/2481098/MeiraGTx Holdings will formally unveil its GMP manufacturing facility in Shannon, Ireland, with the Head of Irish Government, Micheál Martin, in attendance. The facility, online since earlier this year and stretching over 150,000 square feet, is the first commercial-scale ge
- Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet AMDhttps://modernod.com/news/adverum-biotechnologies-announces-first-subject-dosed-with-ixo-vec-in-the-phase-2-luna-trial-for-the-treatment-of-wet-amd/2481097/Adverum Biotechnologies announced that the first subject was dosed in the LUNA phase 2 trial evaluating ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) for the treatment of wet (AMD). “Dosing the first subject in the phase 2 LUNA study brings us a step cl
- Oyster Point's Tyrvaya To Be Covered By the Largest Medicare Pharmacy Benefit Managerhttps://modernod.com/news/oyster-point-pharma-announces-tyrvana-to-be-covered-by-the-largest-medicare-pharmacy-benefit-manager/2481032/Oyster Point Pharma announced that the largest Medicare Pharmacy Benefit Manager in the United States will add Tyrvaya Nasal Spray on its Medicare Part D formularies, effective September 1, 2022. “We are excited to announce this important milestone which will further expand p